Melatonin has solid, well-replicated evidence as a circadian sleep aid at low doses — and a much weaker, largely preclinical evidence base for the antioxidant and lifespan claims that dominate its longevity marketing.
Melatonin's marketing conflates two genuinely distinct hypotheses: melatonin as a circadian sleep regulator, and melatonin as a direct antioxidant with lifespan-extending properties. These have very different levels of human evidence support.
The sleep-regulation claim is genuinely well-supported: multiple meta-analyses of RCTs show modest but consistent improvements in sleep onset latency, particularly for circadian rhythm disorders (jet lag, shift work, delayed sleep phase) and in older adults, whose endogenous melatonin production declines with age. Doses used in these trials are typically low (0.5–3mg) — notably lower than many commercial products, which often contain 5–10mg or more.
Melatonin's proposed direct antioxidant and mitochondrial-protective effects, which underlie most of its "anti-aging" marketing, are supported primarily by in vitro and rodent studies. Rodent lifespan data exists but is mixed and generally not from the large, standardized, multi-site testing programs (like the NIA's Interventions Testing Program) that carry the most weight in the geroscience field for other compounds.
No large human RCT has tested melatonin against a hard longevity outcome. The dose-response relationship for any proposed antioxidant effect in humans, if it exists, is not established — and it is not clear that oral melatonin at supplement doses reaches tissue concentrations comparable to those used in the preclinical studies driving the antioxidant hypothesis.
Independent testing of commercial melatonin products has repeatedly found substantial deviation between labeled and actual content — a documented quality-control issue in the supplement category more broadly, and a relevant caveat for interpreting any real-world outcome data tied to "melatonin use" without knowing the actual dose consumed.
Melatonin's evidence for circadian sleep regulation, at low doses, is genuinely solid RCT-level evidence. Its evidence for direct longevity or anti-aging effects is considerably weaker — largely preclinical, with no human outcome data. These two claims should not be evaluated as if they carry the same evidentiary weight, despite frequently being marketed together.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.